Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Lymphoma, Non-Hodgkin 16Myelodysplastic Syndromes 15Leukemia, Myeloid, Acute 15Leukemia, Lymphocytic, Chronic, B-Cell 15Hodgkin Disease 15Lymphoma, Mantle-Cell 14Multiple Myeloma 13Waldenstrom Macroglobulinemia 12Graft vs Host Disease 12Lymphoma, Large B-Cell, Diffuse 11Lymphoma 11Leukemia 11Lymphoma, Follicular 10Lymphoma, B-Cell, Marginal Zone 10Sarcoma 9Myeloproliferative Disorders 9Burkitt Lymphoma 9Tuberous Sclerosis 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Primary Myelofibrosis 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Neoplasms 6Lymphoma, Large-Cell, Immunoblastic 6Leukemia, Myelomonocytic, Chronic 6Congenital Abnormalities 6Breast Neoplasms 6Myelodysplastic-Myeloproliferative Diseases 5Lymphoma, Large-Cell, Anaplastic 5Lymphangioleiomyomatosis 5

Interventions

Doxorubicin 6pazopanib 5Trabectedin 4Radiotherapy 3temsirolimus 2eribulin 2Sunitinib 2Radiotherapy, Conformal 2Ifosfamide 2Dexamethasone 2sitravatinib 1selinexor 1saracatinib 1romidepsin 1regorafenib 1plitidepsin 1pembrolizumab 1palbociclib 1olaratumab 1milademetan 1liposomal doxorubicin 1lenvatinib 1indolepropanol phosphate 1efatutazone 1cixutumumab 1brigimadlin 1avelumab 1atezolizumab 1Watchful Waiting 1Topotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Liposarcoma × Sirolimus × Clear all
NCT01614795 2018-12-11

Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma

National Cancer Institute (NCI)

Phase 2 Completed
46 enrolled 13 charts
Sarcoma

Fibrosarcoma, Hemangiosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡